| 6.48 -0.22 (-3.28%) | 08-12 12:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.3 | 1-year : | 9.69 |
| Resists | First : | 7.11 | Second : | 8.3 |
| Pivot price | 6.4  |
|||
| Supports | First : | 6.25 | Second : | 5.71 |
| MAs | MA(5) : | 6.65 |
MA(20) : | 6.39 |
| MA(100) : | 6.77 |
MA(250) : | 6.75 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 77.9 |
D(3) : | 83.2 |
| RSI | RSI(14): 50 |
|||
| 52-week | High : | 9.31 | Low : | 5.03 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EPRX ] has closed below upper band by 42.5%. Bollinger Bands are 4.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.87 - 6.9 | 6.9 - 6.93 |
| Low: | 6.62 - 6.65 | 6.65 - 6.69 |
| Close: | 6.64 - 6.7 | 6.7 - 6.75 |
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
Tue, 11 Aug 2026
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results - investingnews.com
Tue, 11 Aug 2026
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Issues Earnings Results - MarketBeat
Tue, 11 Aug 2026
Eupraxia Pharmaceuticals (NASDAQ: EPRX) widens loss to $27.1M while raising $58.6M - Stock Titan
Mon, 10 Aug 2026
Wall Street Analysts See a 145.35% Upside in Eupraxia Pharmaceuticals Inc. (EPRX): Can the Stock Really Move This High? - Yahoo Finance
Fri, 07 Aug 2026
Eupraxia Pharmaceuticals Inc (EPRX) Stock News Today - TradingKey
Fri, 07 Aug 2026
Eupraxia Pharmaceuticals Inc (EPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 51 (M) |
| Held by Insiders | 14.2 (%) |
| Held by Institutions | 41.4 (%) |
| Shares Short | 5,460 (K) |
| Shares Short P.Month | 4,600 (K) |
| EPS | -1.05 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -33.9 % |
| Return on Equity (ttm) | -54.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -33 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -6.18 |
| PEG Ratio | 0 |
| Price to Book value | 3.7 |
| Price to Sales | 0 |
| Price to Cash Flow | -12.97 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|